

**SUPPLEMENTARY TABLE 1. Estimated vaccination coverage by age 24 months\* among children born during 2021-2022,† by selected vaccines and doses and race and ethnicity,§ National Immunization Survey-Child, United States, 2022-2024**

Vaccine/Dose	Race and Ethnicity, % (95% CI)						
	White, NH (referent) (n = 15,402)	Black, NH (n = 2,008)	Hispanic or Latino (Hispanic) (n = 6,008)	AI/AN, NH (n = 256)	Asian, NH (n = 1,318)	NHOPI, NH (n = 84)	Multiple race, NH (n = 2,316)
<b>DTaP¶</b>							
≥3 doses	93.7 (92.9–94.4)	90.0 (87.7–92.0)**	92.0 (90.4–93.4)	91.5 (86.2–95.3)	94.8 (92.8–96.4)	94.0 (89.0–97.2)	93.2 (91.5–94.6)
≥4 doses	83.0 (81.8–84.1)	77.8 (74.8–80.7)**	77.5 (75.3–79.7)**	73.0 (64.0–81.4)**	86.1 (82.8–89.1)	—††	81.0 (78.1–83.7)
<b>Poliovirus (≥3 doses)</b>	92.7 (91.9–93.4)	89.3 (87.0–91.4)**	91.8 (90.4–93.2)	88.9 (81.5–94.3)	95.9 (94.3–97.1)**	94.0 (89.0–97.2)	92.4 (90.5–94.0)
<b>MMR (≥1 dose)§§</b>	91.5 (90.6–92.3)	88.6 (86.2–90.7)**	89.8 (88.0–91.3)	88.8 (82.8–93.4)	95.1 (93.4–96.5)**	93.0 (87.5–96.7)	92.1 (90.3–93.6)
<b>Hib ¶¶¶</b>							
Primary series	92.8 (92.0–93.5)	88.9 (86.6–91.0)**	91.1 (89.5–92.6)	90.6 (84.8–94.9)	94.0 (92.0–95.7)	94.0 (89.0–97.2)	93.0 (91.3–94.5)
Full series	79.0 (77.8–80.2)	74.8 (71.7–77.7)**	75.0 (72.8–77.2)**	76.4 (68.3–83.7)	83.9 (80.5–87.0)**	—††	78.8 (75.6–81.7)
<b>HepB</b>							
Birth dose***	79.8 (78.7–81.0)	77.9 (75.0–80.6)	78.3 (76.0–80.4)	76.0 (67.0–83.2)	84.2 (80.5–87.4)**	—††	78.9 (75.4–82.0)
≥3 doses	91.9 (91.0–92.7)	90.8 (88.6–92.7)	91.3 (89.8–92.6)	86.3 (78.4–92.4)	94.0 (92.2–95.6)**	93.7 (88.7–97.0)	91.9 (89.6–93.8)
<b>VAR (≥1 dose)§§</b>	90.5 (89.6–91.3)	89.1 (86.7–91.1)	89.0 (87.2–90.6)	88.4 (82.4–93.1)	92.1 (89.5–94.2)	92.2 (86.2–96.2)	91.5 (89.6–93.1)
<b>PCV</b>							
≥3 doses	92.1 (91.3–92.9)	89.3 (87.0–91.4)**	90.7 (89.2–92.1)	91.1 (85.7–95.0)	93.4 (91.2–95.1)	93.0 (87.5–96.6)	92.5 (90.7–94.1)
≥4 doses	83.9 (82.8–85.0)	78.1 (75.1–81.0)**	75.0 (72.7–77.3)**	75.6 (66.9–83.4)	85.8 (82.4–88.8)	—††	82.8 (80.1–85.3)
<b>HepA</b>							
≥1 dose	87.1 (86.1–88.0)	84.9 (82.1–87.4)	86.7 (84.9–88.4)	77.7 (67.4–86.5)	91.7 (89.7–93.5)**	92.0 (85.9–96.1)	88.9 (86.5–91.0)
≥2 doses†††	47.2 (45.9–48.6)	43.0 (39.4–46.8)**	46.8 (44.3–49.5)	32.6 (24.3–42.9)**	53.1 (48.4–58.0)**	—††	47.3 (43.6–51.2)
≥2 doses (by 35 months)†††	79.5 (77.8–81.1)	75.9 (71.5–80.1)	78.2 (74.9–81.3)	—††	82.7 (77.7–87.1)	—††	81.5 (76.7–85.9)
<b>Rotavirus (by 8 months)§§§</b>	78.3 (77.1–79.5)	70.0 (66.7–73.1)**	68.2 (65.7–70.7)**	65.7 (55.8–74.3)**	78.1 (73.9–81.8)	83.1 (71.1–90.8)	78.0 (75.0–80.8)
<b>Influenza ≥2 doses¶¶¶</b>	57.0 (55.7–58.4)	39.5 (36.2–42.9)**	50.1 (47.6–52.6)**	33.3 (25.4–42.9)**	71.6 (67.5–75.5)**	—††	58.3 (54.8–61.9)
<b>Combined 7-vaccine series****</b>	70.7 (69.4–72.0)	66.0 (62.7–69.3)**	63.6 (61.1–66.0)**	61.0 (51.3–70.8)	73.9 (69.9–77.8)	—††	69.4 (65.9–72.8)
<b>No vaccinations</b>	1.4 (1.1–1.7)	1.0 (0.6–1.6)	1.2 (0.8–1.9)	—††	0.6 (0.4–1.1)**	—††	0.7 (0.4–1.1)**

**Abbreviations:** AI/AN = American Indian/Alaska Native; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; NH = Non-Hispanic; NHOPI = Native Hawaiian or Other Pacific Islander; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

\* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (also at 35 months for ≥2 HepA doses).

† Data for the 2021 birth year are from survey years 2022, 2023, and 2024; data for the 2022 birth year are considered preliminary and are from survey years 2023 and 2024 (data from survey year 2025 are not yet available).

<sup>§</sup> Children's race and ethnicity were reported by the parent or guardian. Children identified in this report as White, Black, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races were reported by the parent or guardian as non-Hispanic. Children identified as being of multiple races had more than one race category selected. Children identified as Hispanic might be of any race.

<sup>¶</sup> Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

\*\* Statistically significant ( $p < 0.05$ ) difference compared with the referent group.

<sup>††</sup> Estimate not available because the unweighted sample size for the denominator was  $< 30$ , or 95% CI half width/estimate  $> 0.588$ , or 95% CI half-width was  $\geq 10$ .

<sup>§§</sup> Includes children who might have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

<sup>¶¶</sup> Hib primary series: receipt of  $\geq 2$  or  $\geq 3$  doses, depending on product type received; full series: primary series and booster dose, which includes receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product type received.

\*\*\* One dose HepB administered from birth through age 3 days.

<sup>†††</sup> In 2020, the HepA recommendation was revised to two doses between ages 12 and 23 months, at least six months apart, with catch-up vaccination extending to age 18 years. Due to the prolonged eligibility period, coverage estimates for both  $< 24$  months and  $< 35$  months are provided.

<sup>§§§</sup> Includes  $\geq 2$  doses of Rotarix monovalent rotavirus vaccine (RV1), or  $\geq 3$  doses of RotaTeq pentavalent rotavirus vaccine (RV5). (If any dose in the series is either RotaTeq or unknown, default to 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

<sup>¶¶¶</sup> Doses must be at least 24 days apart (four weeks with a four-day grace period); doses could have been received during two influenza seasons.

\*\*\*\* The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes  $\geq 4$  doses of DTaP,  $\geq 3$  doses of poliovirus vaccine,  $\geq 1$  dose of measles-containing vaccine, the full series of Hib ( $\geq 3$  or  $\geq 4$  doses, depending on product type),  $\geq 3$  doses of HepB,  $\geq 1$  dose of VAR, and  $\geq 4$  doses of PCV.